ADR Adherium

Adherium Announces Q1 Fiscal Year 2019 Investor Conference Call

Adherium Announces Q1 Fiscal Year 2019 Investor Conference Call

SAN MATEO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, will host a conference call on Tuesday, October 30, 2018 at 6.30pm ET to discuss first quarter fiscal year 2019 results and business update. Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium’s Chief Financial Officer, David Allinson.

Conference Call details:

Conference ID: 7995294



Dial-in Details:

Australia: 1 800 123 296 or
New Zealand:0800 452 782
Hong Kong: 800 908 865
United States:1 855 293 1544

Webcast:  



For overseas participants, the conference call will commence at:

  • 11.30am on Wednesday, October 31, 2018      (New Zealand Standard Time)
  • 6.30am on Wednesday, October 31, 2018        (Hong Kong Time)
  • 3.30pm on Tuesday, October 30, 2018             (U.S. Pacific Daylight Time)
  • 6:30pm on Tuesday, October 30, 2018             (U.S. Eastern Daylight Time)



A recording of the call will be made available in the ‘Investor Centre’ section of the Company website at and at



About Adherium

Based in Silicon Valley, Adherium is a digital health company dedicated to the health and well-being of people with chronic conditions. The company’s pioneering end-to-end hardware and software solution is clinically proven to promote medication adherence. Adherium’s lead product is the FDA-cleared Bluetooth®-enabled Hailie™ solution for the management of respiratory conditions, which has been shown in clinical studies to reduce severe asthma attacks in adults by as much as 60 percent  and reduce hospital admission rates in children by 80 percent.  Additional applications for the company’s platform technologies are in development. Learn more at adherium.com and hailie.com.

Inquiries

Global:     Vik Panda,
United States:Gilmartin Group, Leigh Salvo,  
Europe: Scott Fleming, ,
Australia:   Pegasus Corporate Advisory, Michael Brown,
Email:  
Web: 
EN
25/10/2018

Underlying

ADRAdherium

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adherium

 PRESS RELEASE
Free
ADR ADHERIUM

Adherium Announces Q1 Fiscal Year 2019 Investor Conference Call

Adherium Announces Q1 Fiscal Year 2019 Investor Conference Call SAN MATEO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a digital health company that improves medication adherence and patient outcomes, will host a conference call on Tuesday, October 30, 2018 at 6.30pm ET to discuss first quarter fiscal year 2019 results and business update. Arik Anderson, Chief Executive Officer will host the call and will be joined by Adherium’s Chief Financial Officer, David Allinson. Conference Call details: Conference ID: 7995294 Dial-in Details: Australia: 1 800 123 296 or New Ze...

October 25, 2018 1 EN
 PRESS RELEASE
Free
ADR ADHERIUM

Adherium Announces Participation in SmartAirLA Effort to Combat Asthma...

Adherium Announces Participation in SmartAirLA Effort to Combat Asthma in Los Angeles with Support from Blue Shield of California Foundation The Program Aims In Part to Develop Better Models for Expanding Data-Based Medication Adherence SAN MATEO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), a leading digital health platform for medication adherence today announced its participation in the launch of the SmartAirLA program to empower communities to reduce the effects and prevalence of asthma in Los Angeles through Internet of Things technology. Using Adherium’s Hailie™ ...

October 3, 2018 1 EN
 PRESS RELEASE
Free
ADR ADHERIUM

Adherium and Vitalus Health Launch Commercial Program to Support Patie...

Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD SAN MATEO, Calif., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of its commercial relationship, Vitalus Health will now bring Adherium’s Hailie™ solution, which hel...

August 23, 2018 1 EN
 PRESS RELEASE
Free
ADR ADHERIUM

Adherium Launches Hailieâ„¢ Solution Direct-to-Consumer in the U.S. fo...

Adherium Launches Hailie™ Solution Direct-to-Consumer in the U.S. for Better Asthma and COPD Management SAN MATEO, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX: ADR), a leading digital health platform that focuses on improving medication adherence and patient outcomes, today officially launched the Hailie™ solution in the U.S., following its recent Food and Drug Administration (FDA) 510(k) over-the-counter clearance to enable sales direct to consumers. The Hailie solution helps patients with asthma and COPD access better care through a seamless digital experience that includes ...

August 13, 2018 1 EN
 PRESS RELEASE
Free
ADR ADHERIUM

Adherium Receives Additional U.S. FDA 510(k) Clearance, Setting in Mot...

Adherium Receives Additional U.S. FDA 510(k) Clearance, Setting in Motion a Full U.S. Consumer Launch of the Hailie™ Solution SAN MATEO, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Adherium (ASX:ADR), an award-winning digital health platform that improves medication adherence, patient outcomes and engagement, today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for over-the-counter (OTC) sales of its Hailie™ sensor for use with ProAir® HFA, Ventolin® HFA and Flovent® HFA asthma inhalers. Adherium’s Hailie sensor, previously known as Smartinhaler™, is a d...

July 26, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch